| Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial YH Kim, M Bagot, L Pinter-Brown, AH Rook, P Porcu, SM Horwitz, ... The lancet oncology 19 (9), 1192-1204, 2018 | 519 | 2018 |
| Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia DS Ritchie, PJ Neeson, A Khot, S Peinert, T Tai, K Tainton, K Chen, ... Molecular Therapy 21 (11), 2122-2129, 2013 | 488 | 2013 |
| Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation S Kamel, L Horton, L Ysebaert, M Levade, K Burbury, S Tan, ... Leukemia 29 (4), 783-787, 2015 | 250 | 2015 |
| Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy CFM Hughes, A Khot, C McCormack, S Lade, DA Westerman, R Twigger, ... Blood, The Journal of the American Society of Hematology 125 (1), 71-81, 2015 | 225 | 2015 |
| First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study A Khot, N Brajanovski, DP Cameron, N Hein, KH Maclachlan, E Sanij, ... Cancer discovery 9 (8), 1036-1049, 2019 | 162 | 2019 |
| Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma P Blombery, ER Thompson, K Jones, GM Arnau, S Lade, JF Markham, ... Haematologica 101 (9), e387, 2016 | 155 | 2016 |
| Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling J Quin, KT Chan, JR Devlin, DP Cameron, J Diesch, C Cullinane, J Ahern, ... Oncotarget 7 (31), 49800, 2016 | 104 | 2016 |
| Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route CE Dearden, A Khot, M Else, M Hamblin, E Grand, A Roy, S Hewamana, ... Blood, The Journal of the American Society of Hematology 118 (22), 5799-5802, 2011 | 93 | 2011 |
| A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results A Spencer, S Harrison, J Zonder, A Badros, J Laubach, K Bergin, A Khot, ... British journal of haematology 180 (1), 41-51, 2018 | 79 | 2018 |
| Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma TA Brighton, A Khot, SJ Harrison, D Ghez, BM Weiss, A Kirsch, H Magen, ... Clinical Cancer Research 25 (13), 3772-3775, 2019 | 61 | 2019 |
| DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM). AK Nooka, K Stockerl-Goldstein, H Quach, A Forbes, MV Mateos, A Khot, ... Journal of Clinical Oncology 38 (15_suppl), 8502-8502, 2020 | 46 | 2020 |
| Panobinostat in lymphoid and myeloid malignancies A Khot, M Dickinson, HM Prince Expert opinion on investigational drugs 22 (9), 1211-1223, 2013 | 46 | 2013 |
| DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (Belamaf) in combination with bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple … R Popat, A Nooka, K Stockerl-Goldstein, R Abonour, R Ramaekers, ... Blood, The Journal of the American Society of Hematology 136 (Supplement 1 …, 2020 | 40 | 2020 |
| Romidepsin for cutaneous T-cell lymphoma HM Prince, M Dickinson, A Khot Future Oncology 9 (12), 1819-1827, 2013 | 26 | 2013 |
| Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma … YH Kim, M Bagot, L Pinter-Brown, AH Rook, P Porcu, SM Horwitz, ... Blood 130, 817, 2017 | 25 | 2017 |
| Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy R Howman, A Thakerer, M Pitman, N Ding, PA Thompson, A Khot, ... Leukemia & lymphoma 51 (12), 2299-2302, 2010 | 20 | 2010 |
| Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing ER Thompson, T Nguyen, Y Kankanige, P Yeh, M Ingbritsen, M McBean, ... Haematologica 106 (1), 313, 2021 | 19 | 2021 |
| T-cell prolymphocytic leukemia A Khot, C Dearden Expert Review of Anticancer Therapy 9 (3), 365-371, 2009 | 17 | 2009 |
| [18F] FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial A Douglas, K Thursky, T Spelman, J Szer, A Bajel, S Harrison, SY Tio, ... The Lancet Haematology 9 (8), e573-e584, 2022 | 16 | 2022 |
| Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement KL Chan, C van der Weyden, C Khoo, S Lade, P Blombery, D Westerman, ... Leukemia & lymphoma 58 (4), 996-998, 2017 | 14 | 2017 |
